James S Blachly

List of Publications by Year in Descending Order

123 papers	2,167 citations	23 h-index	45 g-index
134 ext. papers	2,860 ext. citations	6.3 avg, IF	4.54 L-index

#	Paper	IF	Citations
123	Challenges and Gaps in Clinical Trial Genomic Data Management.. *JCO Clinical Cancer Informatics*, **2022**, 6, e2100193	5.2	
122	Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia. *Nature Communications*, **2021**, 12, 6338	17.4	0
121	Molecular associations, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia (Alliance). *Blood Advances*, **2021**,	7.8	1
120	A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Universally Alloreactive Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood*, **2021**, 138, 1732-1732	2.2	
119	Epigenetic Phenocopying Expands Molecular Risk Assessment in Acute Myeloid Leukemia (Alliance). *Blood*, **2021**, 138, 803-803	2.2	
118	High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance). *Blood*, **2021**, 138, 221-221	2.2	0
117	Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75. *Blood*, **2021**, 138, 4125-4125	2.2	1
116	Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes. *Blood*, **2021**, 138, 685-685	2.2	
115	VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia. *Blood*, **2021**, 138, 270-270	2.2	0
114	Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial. *Blood*, **2021**, 138, 2642-2642	2.2	1
113	CD200R1 Distinguishes Uncommitted Precursors from Functionally Mature NK Cells within the Human Tonsil Stage 4A NK Cell Population. *Blood*, **2021**, 138, 993-993	2.2	
112	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. *Blood*, **2021**, 138, 639-639	2.2	2
111	Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance). *Blood*, **2021**, 138, 226-226	2.2	
110	White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance). *Blood*, **2021**, 138, 3369-3369	2.2	
109	High-Dimensional Analysis Identifies Mechanisms of Gilteritinib Resistance in FLT3-Mutated AML. *Blood*, **2021**, 138, 207-207	2.2	0
108	Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients. *Hematological Oncology*, **2021**,	1.3	
107	Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms. *American Journal of Hematology*, **2021**, 96, E223-E225	7.1	1

106	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. *Leukemia*, **2021**, 35, 1864-1872	10.7	13
105	Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. *Leukemia*, **2021**, 35, 3406-3420	10.7	0
104	A precision medicine classification for treatment of acute myeloid leukemia in older patients. *Journal of Hematology and Oncology*, **2021**, 14, 96	22.4	1
103	Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. *Blood*, **2021**, 137, 3473-3483	2.2	15
102	Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations. *Leukemia*, **2021**, 35, 1188-1192	10.7	2
101	Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. *Cancer Discovery*, **2021**, 11, 626-637	24.4	11
100	Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition. *Clinical Cancer Research*, **2021**, 27, 2352-2366	12.9	4
99	DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. *Genome Research*, **2021**, 31, 747-761	9.7	4
98	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. *Blood*, **2021**, 138, 1570-1582	2.2	1
97	Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged . *Leukemia*, **2020**, 34, 3215-3227	10.7	24
96	Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations. *Blood*, **2020**, 135, 2192-2195	2.2	20
95	Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia. *Cancers*, **2020**, 12,	6.6	6
94	Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. *Cancer Discovery*, **2020**, 10, 394-405	24.4	38
93	Quantifying Hematopoietic Stem Cell Clonal Diversity by Selecting Informative Amplicon Barcodes. *Scientific Reports*, **2020**, 10, 2153	4.9	1
92	A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood*, **2020**, 136, 44-44	2.2	1
91	Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2020**, 136, 22-23	2.2	1
90	Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy. *Blood*, **2020**, 136, 40-41	2.2	
89	Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy. *Blood*, **2020**, 136, 29-30	2.2	

88	LC-FACSeq is a method for detecting rare clones in leukemia. *JCI Insight*, **2020**, 5,	9.9	1
87	TP-0903 is active in models of drug-resistant acute myeloid leukemia. *JCI Insight*, **2020**, 5,	9.9	6
86	Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance). *Blood*, **2020**, 136, 20-21	2.2	2
85	Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance). *Blood*, **2020**, 136, 5-7	2.2	1
84	Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia. *International Journal of Hematologic Oncology*, **2020**, 9, IJH28	1	1
83	Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. *Leukemia*, **2020**, 34, 358-368	10.7	2
82	Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression. *Cancer Research*, **2020**, 80, 561-575	10.1	13
81	Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia. *Leukemia Research*, **2020**, 89, 106297	2.7	3
80	Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia. *Cancer Discovery*, **2020**, 10, 214-231	24.4	16
79	Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts. *NAR Genomics and Bioinformatics*, **2020**, 2, lqaa070	3.7	0
78	Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia. *Journal of Hematology and Oncology*, **2020**, 13, 139	22.4	12
77	Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 26340-26346	11.5	14
76	A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. *American Journal of Hematology*, **2020**, 95, 1457-1465	7.1	1
75	Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of and Expression. *Clinical Cancer Research*, **2020**, 26, 5852-5859	12.9	9
74	Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. *Investigational New Drugs*, **2020**, 38, 340-349	4.3	13
73	Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. *Leukemia and Lymphoma*, **2020**, 61, 387-396	1.9	12
72	Implementation of standardized variant-calling nomenclature in the age of next-generation sequencing: where do we stand?. *Leukemia*, **2019**, 33, 809-810	10.7	0
71	Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. *Leukemia*, **2019**, 33, 1620-1634	10.7	30

70	Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. *Clinical Cancer Research*, **2019**, 25, 6524-6531	12.9	5
69	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML. *Clinical and Translational Science*, **2019**, 12, 641-647	4.9	5
68	Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations. *Blood*, **2019**, 134, 504-504	2.2	27
67	Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia. *Blood*, **2019**, 134, 2526-2526	2.2	0
66	Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia. *Blood*, **2019**, 134, 2072-2072	2.2	
65	The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia. *Blood*, **2019**, 134, 2077-2077	2.2	0
64	Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib. *Blood Advances*, **2019**, 3, 116-118	7.8	21
63	Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. *Blood Advances*, **2019**, 3, 242-255	7.8	23
62	Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. *Leukemia*, **2018**, 32, 1338-1348	10.7	56
61	BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. *Cancer Discovery*, **2018**, 8, 458-477	24.4	67
60	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. *Haematologica*, **2018**, 103, 982-987	6.6	11
59	Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. *Leukemia and Lymphoma*, **2018**, 59, 1008-1011	1.9	19
58	NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. *Leukemia*, **2018**, 32, 2536-2545	10.7	22
57	Additional Gene Mutations Refine the 2017 European Leukemianet (ELN) Classification of Adult Patients (Pts) with De Novo Acute Myeloid Leukemia (AML) Aged . *Blood*, **2018**, 132, 2740-2740	2.2	1
56	Mutations in Genes Associated with Familial Predisposition to Myeloid Neoplasms: Their Frequency and Associations with Pretreatment Characteristics in Adult Patients (Pts) with Presumably Sporadic De Novo Acute Myeloid Leukemia (AML). *Blood*, **2018**, 132, 1478-1478	2.2	
55	Uniparental Disomies (UPD) of Chromosome 13q Is Associated with Shorter Disease-Free Survival in Adult Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). *Blood*, **2018**, 132, 2777-2777	2.2	
54	NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia. *Blood*, **2018**, 132, 3931-3931	2.2	
53	Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment. *Blood*, **2018**, 132, 2305-2305	2.2	1

52	Clinical and Molecular Characteristics of Acute Myeloid Leukemia (AML) Patients with TP53 Mutations and TP73 Mutations. *Blood*, **2018**, 132, 1488-1488	2.2	
51	Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment. *Blood*, **2018**, 132, 4143-4143	2.2	
50	A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML): Alliance Clinical Trials in Oncology (Alliance) Historical Patient Control. *Blood*, **2018**, 132, 1489-1489	2.2	1
49	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. *New England Journal of Medicine*, **2018**, 379, 2517-2528	59.2	455
48	BTK-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. *Journal of Clinical Oncology* , **2017**, 35, 1437-1443	2.2	245
47	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. *Blood*, **2017**, 129, 553-560	2.2	126
46	Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 9629-9634	11.5	12
45	Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. *Cancer Research*, **2017**, 77, 207-218	10.1	15
44	Novel in-frame deletions result in aberrant RNA splicing in CLL patients. *Blood Advances*, **2017**, 1, 995-1008	7.8	8
43	Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. *Blood Advances*, **2017**, 1, 1584-1588	7.8	23
42	Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center. *Blood*, **2017**, 130, 830-830	2.2	25
41	The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. *Oncotarget*, **2017**, 8, 25942-25954	3.3	19
40	MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. *Human Mutation*, **2016**, 37, 1004-12	4.7	5
39	Interferon-Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells. *Journal of Biological Chemistry*, **2016**, 291, 25656-25666	5.4	11
38	Structural characterization of NRAS isoform 5. *Protein Science*, **2016**, 25, 1069-74	6.3	4
37	Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia. *Cancer Discovery*, **2016**, 6, 1036-51	24.4	8
36	Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3). *Leukemia*, **2016**, 30, 1586-9	10.7	9
35	MuCor: mutation aggregation and correlation. *Bioinformatics*, **2016**, 32, 1557-8	7.2	17

34	HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia. *Clinical Cancer Research*, **2016**, 22, 3537-49	12.9	45
33	Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia. *Seminars in Oncology*, **2016**, 43, 265-73	5.5	14
32	Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents. *Current Hematologic Malignancy Reports*, **2016**, 11, 52-60	4.4	5
31	A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. *Blood*, **2016**, 128, 1651-1651	2.2	4
30	Role of Histone Deacetylase-Mediated Gene Silencing in Chronic Lymphocytic Leukemia Progression. *Blood*, **2016**, 128, 2705-2705	2.2	1
29	Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia. *Blood*, **2016**, 128, 2831-2831	2.2	8
28	The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia. *Blood*, **2016**, 128, 3941-3941	2.2	3
27	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. *Blood*, **2016**, 128, 55-55	2.2	7
26	Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia. *Blood*, **2016**, 128, 5598-5598	2.2	3
25	A Distributed International Patient Data Registry for Hairy Cell Leukemia. *Blood*, **2016**, 128, 5986-5986	2.2	
24	The Mutational Patterns Associated with Cytogenetic Subsets of De Novo Acute Myeloid Leukemia (AML): A Study of 1603 Adult Patients (Pts). *Blood*, **2016**, 128, 287-287	2.2	
23	CCND1 and CCND2 Mutations Are Frequent in Adults with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) with t(8;21)(q22;q22). *Blood*, **2016**, 128, 2740-2740	2.2	
22	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. *Blood*, **2016**, 128, 2838-2838	2.2	
21	Exploring the Role of the Recurrent Exportin 1 (XPO1/CRM1) Mutations E571G and E571K in Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 972-972	2.2	0
20	Targeting BTK through microRNA in chronic lymphocytic leukemia. *Blood*, **2016**, 128, 3101-3112	2.2	25
19	Ribosomal revelation. *Blood*, **2016**, 127, 958-9	2.2	1
18	Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. *British Journal of Haematology*, **2016**, 175, 226-236	4.5	43
17	Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 4322-7	11.5	31

16	Separating the wheat from the chaff in cHL. *Blood*, **2015**, 125, 1051-2	2.2	
15	Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. *Haematologica*, **2015**, 100, e18-20	6.6	6
14	Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 1232-1232	2.2	1
13	The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 2911-2911	2.2	2
12	Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 9-13; quiz 13	7.3	24
11	A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies. *Blood*, **2015**, 126, 318-318	2.2	
10	In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease. *Blood*, **2015**, 126, 2471-2471	2.2	
9	PrEMeR-CG: inferring nucleotide level DNA methylation values from MethylCap-seq data. *Bioinformatics*, **2014**, 30, 3567-74	7.2	9
8	Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses. *Clinical Pharmacology and Therapeutics*, **2014**, 96, 182-91	6.1	17
7	Hairy cell leukemia: Update on molecular profiling and therapeutic advances. *Blood Reviews*, **2014**, 28, 197-203	11.1	31
6	PKC-as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. *Blood*, **2014**, 124, 1481-91	2.2	38
5	Quality Control for RNA-Seq (QuaCRS): An Integrated Quality Control Pipeline. *Cancer Informatics*, **2014**, 13, 7-14	2.4	23
4	Expression and prognostic impact of lncRNAs in acute myeloid leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 18679-84	11.5	181
3	Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. *British Journal of Haematology*, **2014**, 167, 19-32	4.5	65
2	Emerging drug profile: cyclin-dependent kinase inhibitors. *Leukemia and Lymphoma*, **2013**, 54, 2133-43	1.9	53
1	Co-Treatment Of Hairy Cell Leukemia and Melanoma With The BRAF Inhibitor Dabrafenib. *Blood*, **2013**, 122, 5311-5311	2.2	2